论文部分内容阅读
背景与目的:由于临床上治疗局部晚期胃癌的效果仍较差,近几年来,新辅助化疗在局部晚期胃癌治疗中的作用又成为热点。本研究探讨FOLFOX改良新辅助化学方案治疗局部晚期胃癌的疗效及毒副作用。方法:2002年12月—2006年12月,有39例局部晚期胃癌患者入组本次临床研究。入组患者接受的新辅助化疗方案:奥沙利铂(Oxa)145mg/m2,第1天,静滴2h,继而亚叶酸钙(CF)500mg及氟尿嘧啶(5-FU)3.5g/m2分别置入微量泵内持续滴注5d,每隔2周为一个周期,共2个周期。观察新辅助化疗后肿瘤原发病灶的缓解情况,并观察毒副反应。结果:所有接受新辅助化疗后的患者临床有效率(CR+PR)为62.0%(24/39),SD11例(28.2%),PD4例(10.3%),39例患者均进行了手术,3例无法手术切除,手术切除率为92.3%(36/39)。毒副反应主要为白细胞减少症、腹泻、恶心、呕吐、脱发、口腔炎。结论:以FOLFOX改良新辅助化疗方案在局部晚期胃癌的治疗中近期疗效显著,耐受性良好。
BACKGROUND & OBJECTIVE: As the clinical effect of locally advanced gastric cancer is still poor, the role of neoadjuvant chemotherapy in the treatment of locally advanced gastric cancer has become a hot spot in recent years. This study was to investigate the efficacy and side effects of FOLFOX modified neoadjuvant chemotherapy in the treatment of locally advanced gastric cancer. Methods: From December 2002 to December 2006, 39 patients with locally advanced gastric cancer were enrolled in this study. The neoadjuvant chemotherapy regimen enrolled in the cohort: oxaliplatin 145 mg / m 2, intravenous infusion 2 h on day 1 followed by 500 mg leucovorin (CF) and 3.5 g / m 2 fluorouracil (5-FU) Into the trace pump continuous infusion 5d, every 2 weeks for a cycle, a total of 2 cycles. To observe the neoadjuvant chemotherapy after the primary tumor remission, and observe the toxicity. Results: All patients undergoing neoadjuvant chemotherapy had a CR (PR) of 62.0% (24/39), SD11 (28.2%) and PD (10.3%). All 39 patients underwent surgery. Cases were not surgical resection, surgical resection rate was 92.3% (36/39). The main side effects of leukopenia, diarrhea, nausea, vomiting, hair loss, stomatitis. Conclusion: FOLFOX modified neoadjuvant chemotherapy in the treatment of locally advanced gastric cancer in the near future significant effect, well tolerated.